GlobalData on MSN11d
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapy
Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...
GlobalData on MSN6d
Trevi’s Phase IIb chronic cough success spikes stock by 71%
The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
ORYZON to Provide Corporate Progress Updates at Several Events in March-April
VanLanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon ...
BioSpace14d
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
Business Insider15d
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL ... randomized, double blind Phase IIb PORTICO trial (final data presented at ECNP-2024). Following receipt of the ...
Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...
Le Lézard6d
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...
Morningstar6d
IRLAB Publishes Preclinical Data on mesdopetam in the Esteemed European Journal of Neuroscience
The Phase Ib and Phase IIa studies showed a good safety and tolerability ... effect compared with current treatment options. A Phase IIb study, completed in 2023, showed that mesdopetam has ...